Myricx Bio

High-Level Overview

Myricx Bio is a UK-based biotechnology company headquartered in London, specializing in the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs) based on inhibitors of *N*-myristoyltransferases (NMT), targeting unmet needs in oncology.[1][2][3] It builds ADCs that deliver selective cytotoxic payloads to cancer cells, serving patients with solid tumors by addressing proteins essential for cancer survival, with preclinical data showing excellent efficacy and safety across multiple antigens and cancer types.[1][5] The company has demonstrated strong growth momentum, raising £4.5 million in seed financing in 2019, followed by a £90 million ($114 million) Series A in recent years, expanding teams, nominating a lead candidate, and planning human trials in 2026.[4][5][8][9]

Origin Story

Myricx Bio, originally launched as Myricx Pharma in 2019, emerged as a spin-out from Imperial College London and the Francis Crick Institute, translating over 15 years of pioneering NMT biology and chemistry research by its co-founders: Professor Ed Tate, Dr. Andrew Bell, and Dr. Roberto Solari.[4][5] The idea stemmed from breakthrough discoveries revealing NMT inhibition's unique mechanism for selective cancer cell killing, particularly effective in previously "undruggable" MYC-driven cancers, secured through exclusive licenses to key patents from the institutions.[4] Early traction came swiftly with £4.5 million seed funding from Sofinnova Partners and Brandon Capital Partners, enabling pipeline prioritization from Stevenage Bioscience Catalyst facilities; pivotal moments include recent awards like the 2025 Cancer Research Horizons Start-Up Achievement Recognition and team expansions post-Series A.[4][5][8]

Core Differentiators

• Novel NMT Inhibitor Payloads for ADCs: Myricx pioneers first-in-class ADCs using proprietary NMT inhibitors, which target an enzyme adding lipid modifications to cancer-critical proteins, achieving complete, durable tumor regressions in preclinical solid tumor models at well-tolerated doses—outperforming traditional payloads via a unique mechanism.[1][2][5]
• Proven Preclinical Superiority: Demonstrated broad efficacy across antigens and cancer types, with high potency, selectivity, and drug-like properties from deep chemistry expertise and systems biology insights.[1][4][5]
• Rapid Pipeline Advancement: Nominated lead development candidate with clinical trials slated for 2026; expanded leadership (e.g., VP Regulatory Affairs David Ellis, Global Head Clinical Operations Penny Fatato) and facilities in London/US to support IND submissions.[5][9]
• Strong IP and Partnerships: Exclusive rights to foundational NMT discoveries; recent antibody license with WuXi Biologics and venture backing enhance scalability.[4][8]

Role in the Broader Tech Landscape

Myricx rides the explosive growth of the ADC market, projected to revolutionize oncology by precisely delivering payloads to tumors while minimizing systemic toxicity, amid surging demand for next-generation payloads beyond auristatins and maytansinoids.[1][2][5] Timing is ideal as NMT inhibition unlocks MYC-driven cancers—historically undruggable—and preclinical successes align with regulatory momentum for ADCs, evidenced by recent approvals and investor enthusiasm (e.g., £90m Series A).[4][5][8] Market forces like rising solid tumor incidence and biotech funding recovery favor Myricx, influencing the ecosystem by validating NMT as a payload class, potentially inspiring competitors and accelerating innovation in targeted therapies.[5]

Quick Take & Future Outlook

Myricx Bio stands on the brink of clinical-stage status, with its lead NMTi-ADC entering trials in 2026, further US expansion, and pipeline maturation poised to deliver transformative oncology options.[5][9] Trends like ADC payload diversification, AI-driven drug design, and global partnerships will propel its trajectory, potentially evolving it into a multi-asset leader challenging incumbents in solid tumors. As a London-headquartered innovator born from academic breakthroughs, Myricx exemplifies how novel biotech payloads can redefine cancer treatment precision.[1][5]